Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: KHS who wrote (19288)	3/6/1999 11:29:00 PM
From: VLAD	Respond to of 23519

KHS, I think that the problem currently with Vivus is that it needs a confirmation of some solid earnings stream. This wont happen until the various European countries launch MUSE and other new countries gain approval and launch. Add to this a domestic partner and we will remove all and any doubt. Although I believe that compared to other peer group stocks the current price absolutely sucks IMO it appears to reflect more of a punishment to the company than anything else. The company beat earnings estimates by 7 cents a share and the stock goes down. Approval of Germany is announced and the stock goes up for a day and then back down. IMO the market makers are determine to keep this stock depressed until they are able to cover the majority of the shares held short. They can't make money by moving the share price up until they first finish up cashing in on the short side. Once they have covered their shares they won't have any reason to short on strength. Watch for insider buying on Edgar come March 15. Watch for MUSE licensing approved in France and Spain this month. Also, expect a big bomb to be dropped on the next FDA report concerning Viagra deaths with a number greater than 400. Most small cap biotech companies have never made a dime and have never marketed a product yet trade well into double digits. Vivus on the other hand has many uncertainties removed regarding MUSE. We have a safe and effective approved product in a growing market. We need marketing in the US and a little more time to get the ball rolling on the international launches. What more does this f###ing market want or expect?